Earlier this year<\/a>, we described an analysis of mitochondrial DNA<\/a> (mtDNA) variants in myalgic encephalomyelitis (ME)\/chronic fatigue syndrome (CFS) patients and healthy controls.<\/p>\n We reported that there was no significant association of haplogroups or singe nucleotide polymorphisms (SNPs) with disease status. Nevertheless, a commentary about our paper appeared (Finsterer and Zarrouk-Mahjoub. J Transl Med14:182, 2016<\/a>) that criticized the association of mtDNA haplogroups with ME\/CFS, a conclusion that was absent from our paper.<\/p>\n The aforementioned commentary also demanded experiments that were outside of the scope of our study, ones that we had suggested as follow-up studies. Because they failed to consult a published and cited report describing the cohorts we studied, the authors also cast aspersions on the method of selection of cases for inclusion.<\/p>\n We reiterate that we observed statistically significant association of mtDNA variants with particular symptoms and their severity, though we observed no association with disease status.<\/p>\n Association of mitochondrial DNA variants with myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS) symptoms<\/a>, by Maureen R. Hanson, Zhenglong Gu, Alon Keinan, Kaixiong Ye, Arnaud Germain and Paul Billing-Ross in<\/span> Journal of Translational Medicine<\/em> 201614:342 [Published: 20 December 2016]<\/p>\n","protected":false},"excerpt":{"rendered":" Article\u00a0abstract: Earlier this year, we described an analysis of mitochondrial DNA (mtDNA) variants in myalgic encephalomyelitis (ME)\/chronic fatigue syndrome (CFS) patients and healthy controls. We reported that there was no significant association of haplogroups or singe nucleotide polymorphisms (SNPs) with … Continue reading